27.9 C
Vientiane
Saturday, September 13, 2025
spot_img
Home Blog Page 753

Everest Medicines Announces NEFECON® Inclusion in China’s Clinical Practice Guideline for IgA Nephropathy and IgA Vasculitis in Chinese Adults (For Public Review)

SHANGHAI, May 23, 2025 /PRNewswire/ — Everest Medicines (HKEX 1952.HK, “Everest”, or the “Company”), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, announced that NEFECON® has been included in the “Clinical Practice Guideline for IgA Nephropathy and IgA Vasculitis in Chinese Adults (For Public Review)” (hereinafter referred to as the “Guideline (Draft)”) on May 21, recommending the etiological treatment with a 9-month course of NEFECON® for all primary immunoglobulin A nephropathy (IgAN) patients who are at risk for disease progression, irrespective of proteinuria levels (2B).

The Guideline (Draft) was presented by Professor Hong Zhang and Professor Jicheng Lv from Peking University First Hospital, during the IgA Nephropathy Forum and IIgANN-China Annual Meeting. It aims to provide crucial guidance for the standardization and optimization of IgA nephropathy diagnosis and treatment. The Guideline (Draft) emphasizes a new disease management strategy of Treat the cause, Treat early, Treat comprehensively.

The Guideline (Draft) recommends that patients with proteinuria ≥ 0.5g/day (or equivalent levels) undergo a renal biopsy and initiate treatment. The treatment goal is to slow the estimated glomerular filtration rate (eGFR) loss to less than 1 ml/min per year. In addition to the two core indicators of proteinuria and eGFR, the Guideline (Draft) also emphasizes routine monitoring of hematuria.

For the first time, the guideline introduces interventions targeting immune-mediated injury, particularly the formation of pathogenic IgA (Gd-IgA1), a key driver of pathogenesis to IgAN. For patients at risk of disease progression, the guideline proposes addressing both symptoms of renal function decline, and initiating therapies targeting immune-mediated injury and CKD progression. NEFECON® is recommended as the preferred treatment to reduce Gd-IgA1. Once short-term treatment goals, namely proteinuria remission (defined as proteinuria < 0.5 g/day, ideally < 0.3 g/day) and stable renal function, are achieved, low-dose maintenance or repeated safe and effective immunotherapy can be considered together with supportive care to ensure that eGFR declines by less than 1 ml/min per year.

“Compared to European and American populations, China has a large IgAN patient population. Chinese IgAN patients experience more rapid disease progression and poorer prognosis. A majority of IgAN patients face the risk of progressing to end-stage renal disease during their lifetime, placing a heavy burden on patients and society.” Said Professor Zhang Hong with Peking University First Hospital, a member of the global steering committee for the Phase 3 clinical trial NefIgArd, chairman of the Chinese Collaborative Group of the International IgAN Federation. “Therefore, IgAN patients require early diagnosis, and a comprehensive treatment approach that spans early intervention, initial therapy, and maintenance therapy. The Guideline (Draft) offers important guidance for clinical practice of IgA nephropathy treatment in China.”

“IgA nephropathy is the most common form of chronic glomerulonephritis worldwide, affecting 40% to 50%[1,2] of kidney biopsy patients in Asian populations, particularly in China. Fifteen years after diagnosis, the kidney survival rate can drop to as low as 40%[1]. This makes the development of guidelines tailored to the Chinese population particularly important.” said Professor Jicheng Lv from Peking University First Hospital. “The Guideline (Draft) updates the treatment strategies and medications for IgAN in China, further standardizing its diagnosis and treatment. It establishes a novel care strategy for Chinese IgAN patients, emphasizing the principles of Treat the cause, Treat early, Treat comprehensively. It recommends treatment with a 9-month course of NEFECON® for IgAN patients at risk of disease progression (2B).”

“We are delighted to see NEFECON® included in the Guideline (Draft), marking a milestone that not only provides Chinese physicians a scientific and precise treatment option but also promises greater benefits and improved quality of life for Chinese IgAN patients.” said Rogers Yongqing Luo, Chief Executive Officer of Everest Medicines. “As the first and only etiological treatment for IgAN fully approved in China, the United States, and Europe, NEFECON® significantly slows eGFR decline, reduces proteinuria, and preserves kidney function. NEFECON® has established itself as a first-line cornerstone therapy for IgAN. Its inclusion in the draft guideline further validates its outstanding clinical advantages, redefining treatment standards and entering a new era of standardized care.”

NEFECON®, as the only in-disease IgA nephropathy (IgAN) treatment has been included in the “KDIGO 2024 Clinical Practice Guideline For The Management Of Immunoglobulin A Nephropathy (IgAN) And Immunoglobulin A Vasculitis (IgAV) (public review draft), recommending treatment with a 9-month course of NEFECON® for patients who are at risk of progressive kidney function loss with IgAN (2B).

Results from the Phase 3 clinical study NefIgArd of the Chinese population shows that NEFECON® reduces kidney function decline by 66%, and delays disease progression to dialysis or kidney transplantation by 12.8 years. During the 2-year treatment and observation period, NEFECON® also demonstrated clinically significant kidney function protection. With the Phase 3 clinical study and real-world evidence, NEFECON® not only fills the gap in etiological treatment for IgAN both domestically and internationally, but also provides clinicians with more compelling treatment options, giving patients a valuable treatment window.

Since May 2025, NEFECON® is indicated to reduce the loss of kidney function in adults with primary immunoglobulin A nephropathy (IgAN) who are at risk for disease progression, irrespective of proteinuria levels. This approval marks NEFECON® as the first and only etiological treatment for IgA nephropathy (IgAN) to receive full approval in China. NEFECON® was also included in the National Reimbursement Drug List in November 2024.

About NEFECON®

NEFECON® is a patented oral, delayed release formulation of budesonide, a corticosteroid with potent glucocorticoid activity and weak mineralocorticoid activity that undergoes substantial first pass metabolism. The formulation is designed as a delayed release capsule that is enteric coated so that it remains intact until it releases budesonide to the distal ileum. Each capsule contains coated beads of budesonide that target mucosal B-cells present in the ileum where the disease originates, as per the predominant pathogenesis models.

In June 2019, Everest Medicines entered into an exclusive, royalty-bearing license agreement with Calliditas Therapeutics, which gives Everest Medicines exclusive rights to develop and commercialize NEFECON® in mainland China, Hong Kong, Macau, Taiwan (China) and Singapore. The agreement was extended in March 2022 to include South Korea as part of Everest Medicines’ territories.

About Everest Medicines

Everest Medicines is a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing transformative pharmaceutical products and vaccines that address critical unmet medical needs for patients in Asian markets. The management team of Everest Medicines has deep expertise and an extensive track record from both leading global pharmaceutical companies and local Chinese pharmaceutical companies in high-quality discovery, clinical development, regulatory affairs, CMC, business development and operations. Everest Medicines has built a portfolio of potentially global first-in-class or best-in-class molecules in the company’s core therapeutic areas of renal diseases, infectious diseases and autoimmune disorders. For more information, please visit its website at www.everestmedicines.com.

Forward-Looking Statements:

This news release may make statements that constitute forward-looking statements, including descriptions regarding the intent, belief or current expectations of the Company or its officers with respect to the business operations and financial condition of the Company, which can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” “confident” and similar statements. Such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, or other factors, some of which are beyond the control of the Company and are unforeseeable. Therefore, the actual results may differ from those in the forward-looking statements as a result of various factors and assumptions, such as future changes and developments in our business, competitive environment, political, economic, legal and social conditions. The Company or any of its affiliates, directors, officers, advisors or representatives has no obligation and does not undertake to revise forward-looking statements to reflect new information, future events or circumstances after the date of this news release, except as required by law.

References:

1.       Shen X, et al. Nephrol Dial Transplant. 2024 Nov 19: gfae252.

2.       Li G, et al. J Nephrol . 2025 Mar 26. doi: 10.1007/s40620-025-02261-1. Online ahead of print.

SUNMI Opens Its First North American Store in Atlanta

ATLANTA, May 23, 2025 /PRNewswire/ — On May 22, 2025, SUNMI, a global leader in smart business IoT solutions, celebrated the grand opening of its first North American store in Atlanta’s central business district, unveiling the upgraded digital transformation experience space “SUNMI Home 2.0.” The event was attended by SUNMI founder Jack Lin, rotating president and CMO Sam Su, and key ecosystem partners, marking a significant milestone. This flagship store embodies SUNMI’s innovative “Regional Headquarters & Flagship Experience Center” model, aimed at accelerating localized digital transformation in the region.

New Third-Generation Product Matrix: Setting a Benchmark for Smart Terminals

SUNMI Home 2.0 showcases its third-generation flagship products, including the global debut of the SUNMI CPad, L3, M3, and the new category Flex 3. This extensive array of smart terminals is supported by SUNMI’s integrated software capabilities, and offers the SUPER Solution dual-system and Hyper Wi-Fi network solutions. Alongside global partners, SUNMI is building a digital engine for the restaurant, retail, and logistics sectors across North America.

SUNMI Home 2.0: A Powerhouse for Business Innovation

Unlike traditional retail outlets, this upgraded SUNMI Home 2.0 seamlessly combines offline experiences with online services:

  1. Offline Operations: The store will host “Channel Co-Building Days” and “Industry Open Days,” inviting partners to engage in customized solution discussions and collaborating with local businesses for regular digital transformation practice sessions. Local retail and restaurant representatives demonstrated how SUNMI devices enhance space utilization and customer experience at the grand opening.
  2. Online Upgrades: The upcoming “SUNMI Home” version will integrate 3D VR experiences and an intelligent recommendation system, allowing users to easily locate nearby service points through a map feature, offering tailored industry solutions with a single tap.

Strategic Expansion: Localized Strategies Activate the North American Market

Sam Su highlighted that “Atlanta is a central hub connecting the east and west coasts of North America. Leveraging this headquarters, regional offices and local warehouses along with employees, we will provide customized BIoT solutions through our global supply chain and production network. Our ecosystem partners are essential as we work together to deliver comprehensive industry solutions that enhance user experience.”

Looking Ahead: Driving Business 4.0 Growth

With the Atlanta flagship store operational, SUNMI plans to open five additional SUNMI Homes in the U.S. by 2025, improving customer experience and collaboration through interconnected services.

Or Tor Kor Elevates Thai Agricultural Products on the Global Stage with “IFEX Connect 2025” in Manila


BANGKOK, THAILAND – Media OutReach Newswire – 23 May 2025 – The Marketing Organization for Farmers (Or Tor Kor), under the Ministry of Agriculture and Cooperatives, is set to spotlight Thailand’s high-value agricultural products at IFEX Connect 2025, taking place from May 22–24, 2025 at the World Trade Center Metro Manila, Philippines. This international showcase is held under the banner of the “Thailand Intertrade: High-Value Tropical Agricultural Products to the Global Market” initiative.

unnamed

The Thailand Intertrade project aims to expand international market opportunities for premium Thai agricultural goods through the strategic use of soft power and the Bio-Circular-Green (BCG) Economy model. These efforts align with national policies focused on sustainable economic development and adding value to local agricultural products.

Mr. Panitan Meechaiyo, Director of the Marketing Organization for Farmers, remarked:

“Or Tor Kor is committed to propelling Thai tropical agricultural products—renowned for their uniqueness and quality—into global markets. IFEX Connect 2025 will serve as a strategic roadshow platform to enhance global recognition of Thai agricultural excellence, while ensuring long-term, stable income for Thai farmers.”

The event will feature a comprehensive exhibition of premium Thai agricultural products, including both fresh produce and processed goods. Highlighted items include jasmine rice, sticky rice, brown rice, white rice, crispy coconut, freeze-dried durian and mangosteen, soft-dried pineapple, guava, jackfruit, mango, and roselle. All products are sourced from qualified farmer groups and producers that meet international standards in quality, safety, and environmental responsibility.

In addition to the product showcase, IFEX Connect 2025 will host business matching sessions, Thai cultural performances, and live cooking demonstrations, delivering a full cultural experience. These elements aim to reinforce the image of Thai agricultural products as “Contemporary Cultural Products” that resonate with modern global consumers.

The Philippines was chosen as the launch market for this initiative due to its strong and growing demand for Thai agricultural products and its strategic location as a gateway to the ASEAN region.

Event Details:

  • Event: IFEX Connect 2025
  • Dates: May 22–24, 2025
  • Location: Booths L16–17, Hall D, World Trade Center Metro Manila, Philippines

A large turnout of international importers, buyers, and consumers is expected, creating new commercial opportunities for Thai producers and supporting sustainable growth in Thailand’s agricultural economy.

Hashtag: #OrTorKor

The issuer is solely responsible for the content of this announcement.

Volvo Trucks Driver Challenge – A step towards Decarbonizing the transportation industry, while maximizing on fuel economy

GOTHENBURG, Sweden, May 23, 2025 /PRNewswire/ — The seventh edition of the competition focused on the skills that make a real difference for productivity and sustainability in the modern transport business. The 2 key champions were Mr. Fatorrahman from Indonesia [Off-Road Category] and Mr. Euihwan Choi from Korea [On-Road Category].

Global Finals Flag-Off
Global Finals Flag-Off

The aim of the Driver Challenge is to draw attention to the important work done by truck drivers. It is also a way of attracting young people to the job, which offers good career opportunities. The transport industry is constantly growing and there is now a shortage of trained drivers all over the world. To help our customers to recruit and retain skilled drivers, we have been focusing for many years on the design of the driver’s environment and the drivability of our trucks. The concept “You win, we all win” puts truck drivers in focus, highlighting the vital role they play in ensuring everybody wins. It reminds customers that there is always room for improvement when it comes to driving skills – and that it’s well worth the effort.

The Volvo Trucks Driver Challenge brings together all the different challenges that truck drivers face every day. Their skills are often the decisive factor in the productivity and profitability of our customers. Drivers also make a major contribution to road safety. The finals gave us the opportunity to see incredibly skillful drivers doing an impressive job of handling their trucks.

Ms. Anna Engblom, Managing Director for Southeast Asia & Japan at Volvo Trucks said, “The Driver Challenge is our way of bringing Volvo’s deep expertise in fuel economy to our customers, delivering these benefits throughout the entire lifespan and operation of their trucks. This competition empowers drivers to enhance their driving skills, improve fuel efficiency, and prioritize safety. Using less fuel is not only beneficial for our customers but also for the environment.” She continued to say ” Volvo Connect scores measure driver performance, providing a Fuel Efficiency Score based on speed adaptation, engine and gear utilization, anticipation and braking, and standstill. Striving for a high score reduces costs, CO2 emissions, and enhances safety and vehicle longevity – key aspects of the Drivers’ Challenge.”

The Volvo Trucks Driver Challenge has been running globally since 2009 and this year’s competition attracted 13 markets in the Middle East, Asia, Oceania and Australia. In the sub-category segment, the winners for each were [On-Road & Off-Road]

  • Best Fuel-Efficient Driving: Anthony Marshall, Australia & Sangyoun Park, Korea
  • Best Transport Mission / High Productivity: Amnart Phengphet, Thailand & Ryan Balanueco, Philippines
  • On-Time Delivery: Bedirhan Ugur Karsli, Turkey & Sangyoun Park, Korea

 

Off-Road Champion
Off-Road Champion

On-Road Champion
On-Road Champion

Volvo Trucks Driver Challenge – A step towards Decarbonizing the transportation industry, while maximizing on fuel economy

GOTHENBURG, Sweden, May 22, 2025 /PRNewswire/ — The seventh edition of the competition focused on the skills that make a real difference for productivity and sustainability in the modern transport business. The 2 key champions were Mr. Fatorrahman from Indonesia [Off-Road Category] and Mr. Euihwan Choi from Korea [On-Road Category].

Global Finals Flag-Off
Global Finals Flag-Off

The aim of the Driver Challenge is to draw attention to the important work done by truck drivers. It is also a way of attracting young people to the job, which offers good career opportunities. The transport industry is constantly growing and there is now a shortage of trained drivers all over the world. To help our customers to recruit and retain skilled drivers, we have been focusing for many years on the design of the driver’s environment and the drivability of our trucks. The concept “You win, we all win” puts truck drivers in focus, highlighting the vital role they play in ensuring everybody wins. It reminds customers that there is always room for improvement when it comes to driving skills – and that it’s well worth the effort.

The Volvo Trucks Driver Challenge brings together all the different challenges that truck drivers face every day. Their skills are often the decisive factor in the productivity and profitability of our customers. Drivers also make a major contribution to road safety. The finals gave us the opportunity to see incredibly skillful drivers doing an impressive job of handling their trucks.

Ms. Anna Engblom, Managing Director for Southeast Asia & Japan at Volvo Trucks said, “The Driver Challenge is our way of bringing Volvo’s deep expertise in fuel economy to our customers, delivering these benefits throughout the entire lifespan and operation of their trucks. This competition empowers drivers to enhance their driving skills, improve fuel efficiency, and prioritize safety. Using less fuel is not only beneficial for our customers but also for the environment.” She continued to say ” Volvo Connect scores measure driver performance, providing a Fuel Efficiency Score based on speed adaptation, engine and gear utilization, anticipation and braking, and standstill. Striving for a high score reduces costs, CO2 emissions, and enhances safety and vehicle longevity – key aspects of the Drivers’ Challenge.”

The Volvo Trucks Driver Challenge has been running globally since 2009 and this year’s competition attracted 13 markets in the Middle East, Asia, Oceania and Australia. In the sub-category segment, the winners for each were [On-Road & Off-Road]

  • Best Fuel-Efficient Driving: Anthony Marshall, Australia & Sangyoun Park, Korea
  • Best Transport Mission / High Productivity: Amnart Phengphet, Thailand & Ryan Balanueco, Philippines
  • On-Time Delivery: Bedirhan Ugur Karsli, Turkey & Sangyoun Park, Korea
Off-Road Champion
Off-Road Champion

 

On-Road Champion
On-Road Champion

Photo – https://laotiantimes.com/wp-content/uploads/2025/05/0d3a9497_1-1.jpg
Photo – https://laotiantimes.com/wp-content/uploads/2025/05/offroad_champion-1.jpg
Photo – https://laotiantimes.com/wp-content/uploads/2025/05/on_road_champion-1.jpg

ThunderSoft Showcases Japan-Focused Smart Vehicle Solutions at Automotive Engineering Exposition 2025 Yokohama

YOKOHAMA, Japan, May 22, 2025 /PRNewswire/ — May 21–23, 2025,ThunderSoft, a global leader in intelligent automotive software, made its debut at the Automotive Engineering Exposition 2025 Yokohama (Booth No. 2-249), presenting its next-generation smart vehicle solutions tailored for the Japanese market. Under the themes of One-Stop Solution, AI and Advanced Technologies, and Global Enablement, ThunderSoft demonstrated its comprehensive capabilities in helping automakers accelerate carbon neutrality, advance connected car technologies, and drive the scale adoption of Software-Defined Vehicles (SDVs) in Japan.

Company Profile & Global Presence

Founded in 2008, ThunderSoft is a globally recognized provider of intelligent operating systems and edge AI technologies. Listed on the Shenzhen Stock Exchange since 2015, the company operates in more than 40 cities worldwide and employs over 15,000 professionals. Since entering the automotive sector in 2013, ThunderSoft has developed a comprehensive full-stack solution centered on its proprietary AquaDrive OS, a next-generation operating system designed for smart vehicles. The company’s solutions span smart cockpits, advanced driver assistance systems (ADAS), vehicle OS, and high-performance computing (HPC) platforms—powering over 50 million vehicles globally.

Solutions Optimized for the Japanese Automotive Market

At the expo, ThunderSoft introduced several state-of-the-art technologies designed with Japanese automakers and tier-1 suppliers in mind, attracting significant attention and praise from attendees.

■ AquaDrive OS 1.0 Evo – AI-Native OS for HPC-Based Architectures

The AquaDrive OS 1.0 Evo is an AI-native smart cockpit operating system developed on the Qualcomm 8775 4th-generation platform. Officially released in April 2025, the OS has already been adopted by multiple global OEMs. Notably, Toyota showcased a concept vehicle featuring AquaDrive OS at the Shanghai Auto Show earlier this year.

Key innovations include:

  • Immersive 3D HMI for an intuitive and engaging user experience
  • Edge–cloud–device AI collaboration for personalized services
  • Modular architecture supporting cross-domain integration
  • Enhanced in- and out-of-vehicle safety through precision vision and AI perception
  • Full compatibility with global ecosystems for streamlined mass production

More than just an operating system, AquaDrive OS 1.0 Evo serves as a smart life enabler, seamlessly connecting the car and home to deliver next-generation user experiences.

■ Lightweight ZCU Virtualization Platform – Co-Developed with Renesas Electronics

ThunderSoft has partnered with Renesas Electronics to jointly develop a lightweight ZCU virtualization platform, addressing the growing complexity of in-vehicle electronic architectures. Leveraging ThunderSoft’s expertise in multi-chip OS integration and Renesas’ high-performance MCUs, this platform enables efficient consolidation of multiple functional domains on a single ECU—without compromising performance. This helps OEMs simplify controller design, reduce BOM costs, and enhance system reliability, making it ideal for next-gen domain-centralized vehicle architectures.

■ KanziOne – Next-Generation HMI Development Toolchain

KanziOne is a unified HMI development platform that streamlines the entire interface design process from concept to testing.

Two featured solutions included:

  • Kanzi for MCUs : Enables efficient 2D/2.5D rendering on low-power embedded MCUs. Already applied in IVI, HVAC, armrest displays, HUDs, and smart keys, it is compatible with Infineon Traveo II and Renesas RH850 platforms—allowing OEMs to standardize HMI designs across vehicle platforms.
  • Kanzi Author with Generative AI : Integrates generative AI technology to automate the design-to-code pipeline. By transforming design sketches into interface structures and generating interaction logic automatically, it significantly boosts speed and flexibility in HMI development.

Driving Innovation in Collaboration with Japanese Partners

ThunderSoft continues to expand its global innovation footprint while forming deep collaborations with leading automotive OEMs. With a long-term commitment to the Japanese market, the company aims to deliver continuous value and support the global leadership of Japan’s mobility industry in both technology and business performance.

FDA Clearance of Investigational New Drug Application Received for Novel EGFR/HER3 Bispecific Antibody-Drug Conjugate AVZO-1418/DB-1418

Phase 1/2 first-in-human clinical study planned this year

SHANGHAI and SAN DIEGO, May 23, 2025 /PRNewswire/ — Duality Biotherapeutics (“DualityBio”, HKEX:09606) partner Avenzo Therapeutics, Inc. (“Avenzo”), a clinical-stage biotechnology company developing next-generation oncology therapies, today announced clearance by the U.S. Food and Drug Administration (FDA) of its investigational new drug application (IND) for AVZO-1418/DB-1418, a potential best-in-class, novel EGFR/HER3 bispecific antibody-drug conjugate (ADC).

On January 7th, 2025,  DualityBio and Avenzo announced that they entered into an exclusive license agreement, pursuant to which Avenzo will develop, manufacture and commercialize AVZO-1418/DB-1418, a potential best-in-class EGFR/HER3 bispecific ADC, globally (excluding Greater China).

Under the IND, a Phase 1/2 first-in-human, open-label clinical study is planned to initiate later this year. The Phase 1 portion will assess the safety, tolerability, and preliminary clinical activity of AVZO-1418/DB-1418 as a single agent and in combination therapy in patients with advanced solid tumors.

Preclinical data for AVZO-1418/DB-1418 were presented for the first time at the American Association for Cancer Research (AACR) Annual Conference in April 2025 and highlighted AVZO-1418/DB-1418’s novel design and additive binding affinity in EGFR and HER3 co-expressing tumor cells. In addition, AVZO-1418/DB-1418 demonstrated efficacy in in vivo xenograft models across multiple tumor types, including in an EGFR TKI-resistant NSCLC model.

About DualityBio

Duality Biotherapeutics (HKEX:09606) is a clinical-stage biotech company dedicated to the discovery and development of next-generation ADCs to treat cancer and autoimmune diseases. DualityBio has successfully built several cutting-edge ADC technology platforms with global intellectual property rights. Leveraging a robust pipeline, DualityBio is conducting multiple global clinical trials across 17 countries and has enrolled over 2,000 patients for multiple clinical-stage ADC candidates.

Additionally, DualityBio has established strategic collaborations with global MNCs and leading biotech innovators. As a global ADC powerhouse, DualityBio is developing novel ADCs, including bispecific ADC candidates, novel-payload ADC candidates, and autoimmune ADC candidates. For more information, please visit www.dualitybiologics.com.

Media Contact: PR@dualitybiologics.com

Manhattan Associates Unveils Agentic AI Innovation at Momentum 2025

SYDNEY, May 23, 2025 /PRNewswire/ — Kicking off Momentum 2025,  Manhattan Associates Inc. (NASDAQ: MANH) today announced sweeping Agentic AI support within Manhattan Active® solutions that includes intelligent, autonomous digital agents to revolutionise supply chain commerce execution, optimisation, and user experiences.

Adobe Stock
Adobe Stock

These out-of-the-box AI agents, powered by large language models (LLMs) and Manhattan’s cloud-native, all-microservice API architecture, will autonomously perform tasks, adapt to changing conditions, and dynamically orchestrate workflows. This breakthrough marks a generational leap from traditional chatbots and static workflow configurations to dynamic, intelligent, and situationally aware orchestration across the entire supply chain and commerce lifecycle.

Among the first groundbreaking AI agents announced are the Intelligent Store Manager, Labor Optimiser Agent, Wave Inventory Research Agent, Contextual Data Assistant, and Virtual Configuration Consultant. These digital agents allow users to interact with Manhattan applications using natural language, understand complex requests, bypass traditional interfaces to surface data, drive optimisation, and efficiently resolve disruptions in real time across critical supply chain commerce operations.

To further empower customers and partners to innovate at their own pace, the company also launched Manhattan Agent Foundry™, a groundbreaking platform designed to enable organisations to rapidly build and deploy their own agents within the Manhattan ecosystem. Customers can now create specialised agents tailored to their unique processes and preferences, drastically reducing time-to-value, increasing automation scalability, enhancing productivity, and delivering tangible business value. They can also lean on Manhattan or third-party partners to develop these specialised agents.

“Agentic AI isn’t just another feature; it’s a transformative innovation capability tailored to redefine the future of supply chain commerce,” said Sanjeev Siotia, CTO at Manhattan. “By opening up Agent Foundry to our customers and partners, we’re ensuring that AI agent creation will not be constrained by vendor development cycles. This is part of Manhattan’s ongoing commitment to path-breaking technology that heightens efficiency and resiliency. Our best-in-class customer base now has the power to create thousands of digital agents, limited only by their imagination.”

All agents built in Manhattan Agent Foundry are compatible with emerging industry standards, including A2A and MCP protocols, ensuring seamless interoperability with third-party agent platforms such as Google Agentspace. This reinforces Manhattan’s desire to make Agentic AI a key enabler of an interconnected, AI-driven enterprise ecosystem.

Agentic AI assistants and Agent Foundry will be generally available starting Spring 2025.

Receive up-to-date product, customer and partner news directly from Manhattan on LinkedIn.

ENDS

ABOUT MANHATTAN ASSOCIATES:
Manhattan Associates is a global technology leader in supply chain and omnichannel commerce. We unite information across the enterprise, converging front-end sales with back-end supply chain execution. Our software, platform technology and unmatched experience help drive both top-line growth and bottom-line profitability for our customers. 

Manhattan Associates designs, builds and delivers leading edge cloud solutions so that across the store, through your network or from your fulfillment center, you are ready to reap the rewards of the omnichannel marketplace. For more information, please visit www.manh.com.